Medicare Overpaid For Prescription Drugs With New Generic Versions Because Of Delay In Incorporating New Prices Into Payment Calculations, HHS OIG Rep
Medicare overpaid for irinotecan, a cancer drug sold by Pfizer under the name Campostar, by $6.5 million in March because of a delay in updating its pricing formula, according to a report released on Tuesday by the HHS Office of Inspector General, Bloomberg/Los Angeles Times reports. A generic version of the drug was approved for sale on Feb. 20.
Mail this post 
Health is the Most Precious Asset to us! Just willing to share with you what I have learned from Nutriotional Immunology.
